ClinicalTrials.Veeva

Menu

Evaluation of the Diagnostic Value of Video-oculography in CANVAS Neuronopathies (VOG-Neuropat)

C

Centre Hospitalier Universitaire de Nīmes

Status

Completed

Conditions

Cerebellar Ataxia

Treatments

Other: None, pure observationnal study

Study type

Observational

Funder types

Other

Identifiers

NCT05278091
Local/2022/II-02

Details and patient eligibility

About

Cerebellar ataxia syndrome with neuropathy and vestibular areflexia (CANVAS) is a genetic pathology of recent discovery (bi-allelic expansion in intron 1 of the RFC1 gene with AAGG repetition). The clinical picture is protean, associating a neuronopathy, a bilateral vestibulopathy evidenced by an alteration of the oculovestibular reflex (VOR), an atrophy of the cerebellum and a chronic cough.

In the initial stage of the disease the clinical picture is heterogeneous and often incomplete. Ataxia at the beginning of the disease may be the consequence of peripheral nervous system involvement (neuronopathy) and the cerebellar syndrome may manifest itself clinically late.

Eye movement involvement in central nervous system pathologies is common (4). Oculomotor abnormalities are often subclinical and sometimes exclusively identifiable by an instrumental study, video-oculography (VOG) (5).

VOG is a non-invasive examination of eye movements, which is increasingly used in the differential diagnosis of neurodegenerative syndromes (6). This examination allows, among other things, to identify oculomotor anomalies, even discrete and asymptomatic, by studying the combined movements of the eyes and the oculocephalic movements.

The study of oculomotricity by VOG can therefore potentially contribute to the early differential diagnosis of ataxiating neuropathies, including CANVAS, by revealing infra-clinical oculomotor abnormalities correlated with a cerebellar expectation (knowing the role of the dorsal vermis in the precision of saccades and pursuits).

Enrollment

56 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Patients followed at the University Hospital of Nîmes between 2018-2021

  • Age > 18 years
  • Patients with CANVAS with genetic confirmation (RFC1 gene mutation)
  • Patients with axonal neuropathy, autoimmune neuronopathy and anti-MAG neuropathy
  • Healthy controls

Trial design

56 participants in 3 patient groups

Patients with CANVAS with genetic confirmation
Description:
Patients with CANVAS with genetic confirmation (RFC1 gene mutation)
Treatment:
Other: None, pure observationnal study
others patients
Description:
Patients with axonal neuropathy, autoimmune neuronopathy and anti-MAG neuropathy
Treatment:
Other: None, pure observationnal study
Healthy controls
Description:
Patients without CANVAS or other neuropathy
Treatment:
Other: None, pure observationnal study

Trial contacts and locations

1

Loading...

Central trial contact

Ioana ION

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems